<< Pharmacology and Therapeutics Advisory Committee (PTAC)
Funding Applications
PTAC reviews funding applications from pharmaceutical suppliers, health professionals and consumer groups. Guidelines for making these submissions are available here:
Guidelines for Submission to PHARMAC and PTAC on New Chemical Entities and Generic Pharmaceuticals) (13 pages, 220 KB)
Recommended methods to derive clinical inputs for proposals to PHARMAC (37 pages, 332 KB)
New Funding Applications
The following applications will be considered at the November 2009 meeting. This is not necessarily a complet list, and is published in accordance with the Terms of Reference for the Phamacology and Therapeutics Advisory Copmmittee and PTAC Subcommittees 2008.
- Etravirine (Intelence) antiretroviral for HIV. Janssen-Cilag; submitted 03/09/2009
- Rivaroxaban (Xarelto) for venous thromobembolism prophylaxis. Bayer; submitted 09/09/2009
- Budesonide/eformoterol (Symbicort Turbuhaler) for asthma. AstraZeneca; submitted 15/09/2009
- Sunitinib (Sutent) for advanced renal cell carcinoma. Pfizer; submitted 15/09/2009
- Gemcitabine (Gemzar) for pancreatic cancer. Gastrointestinal Cancer Special Interest Group of the New Zealand Association of Cancer Specialists; submitted 15/09/2009
- Dornase alpha for cystic fibrosis. Individual; submitted 15/09/2009
- Vildagliptin (Galvus) for type 2 diabetes. Novartis; submitted 12/06/2009
- Sitagliptin and metformin (Janumet)and sitagliptin (Januvia) for type 2 diabetes. Merck Sharp & Dohme; submitted 12/06/2009
- Insulin glulisine (Apidra) for type 1 and 2 diabetes. Sanofi Aventis; submitted 15/06/2009
Historic Funding Applications
A list of applications received for new investments since 1 December 2008 is available here (3 pages, 65 KB)
A list of applications received for new investments between 1 July 2002 and 30 November 2008 is available here (19 pages, 107 KB).
Page updated on 12 Oct 2009
Linked documents
Version 1.2 of Application Guidelines (13 pages, 220 KB)
GUIDELINES FOR APPLICATIONS TO PHARMAC AND PTAC ON NEW CHEMICAL ENTITIES, NEW INDICATIONS AND FORMULATIONS, COMBINATION PRODUCTS AND GENERIC PHARMACEUTICALS Version 1.2 2005 Minor amendments made December 2006 and May 2008 Please note that these Guidelines are currently under review.…
Recommended methods to derive clinical inputs for proposals to PHARMAC (37 pages, 332 KB)
Recommended methods to derive clinical inputs for proposals to PHARMAC Version 1B 20 July 2005 R8-0-0 #62465 Table of contents Recommended methods to derive clinical inputs for proposals to PHARMAC ….. 1 Table of contents… 2 Context of these recommendations…
Applications received since 1 November 2008 (3 pages, 65 KB)
Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC’s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Applications Received…
Applications received since 1 July 2002 (19 pages, 107 KB)
Applications received for new investments since 1 July 2002: As published in the Guidelines for the Pharmacology and Therapeutics Advisory Committee (PTAC) and its Subcommittees 2002, PHARMAC is, from 1 July 2002, making the existence of applications for new investments…
